DE69115989D1 - Verwendung von 1-(2-Naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur Herstellung eines Medikaments zur Behandlung von zerebralen und neuronalen Krankheiten - Google Patents

Verwendung von 1-(2-Naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur Herstellung eines Medikaments zur Behandlung von zerebralen und neuronalen Krankheiten

Info

Publication number
DE69115989D1
DE69115989D1 DE69115989T DE69115989T DE69115989D1 DE 69115989 D1 DE69115989 D1 DE 69115989D1 DE 69115989 T DE69115989 T DE 69115989T DE 69115989 T DE69115989 T DE 69115989T DE 69115989 D1 DE69115989 D1 DE 69115989D1
Authority
DE
Germany
Prior art keywords
naphthylethyl
tetrahydropyridine
trifluoromethylphenyl
cerebral
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69115989T
Other languages
English (en)
Other versions
DE69115989T2 (de
Inventor
Francois Xavier Coude
Jacqueline Fournier
Umberto Guzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of DE69115989D1 publication Critical patent/DE69115989D1/de
Application granted granted Critical
Publication of DE69115989T2 publication Critical patent/DE69115989T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
DE69115989T 1990-05-22 1991-05-21 Verwendung von 1-(2-Naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur Herstellung eines Medikaments zur Behandlung von zerebralen und neuronalen Krankheiten Expired - Lifetime DE69115989T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (2)

Publication Number Publication Date
DE69115989D1 true DE69115989D1 (de) 1996-02-15
DE69115989T2 DE69115989T2 (de) 1996-08-22

Family

ID=9396855

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69115989T Expired - Lifetime DE69115989T2 (de) 1990-05-22 1991-05-21 Verwendung von 1-(2-Naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur Herstellung eines Medikaments zur Behandlung von zerebralen und neuronalen Krankheiten
DE69132797T Expired - Fee Related DE69132797T2 (de) 1990-05-22 1991-05-21 Verwendung von Vincristin zur Auswertung von Wirkstoffen in Zentralnervensystems

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69132797T Expired - Fee Related DE69132797T2 (de) 1990-05-22 1991-05-21 Verwendung von Vincristin zur Auswertung von Wirkstoffen in Zentralnervensystems

Country Status (17)

Country Link
US (3) US5229389A (de)
EP (2) EP0458696B1 (de)
JP (2) JP2618115B2 (de)
KR (1) KR0181330B1 (de)
AT (2) ATE207747T1 (de)
BR (1) BR9105015A (de)
CA (2) CA2365832C (de)
CY (1) CY2283B1 (de)
DE (2) DE69115989T2 (de)
DK (2) DK0458696T3 (de)
FR (1) FR2662355B1 (de)
HK (1) HK1001471A1 (de)
HU (1) HU208922B (de)
IE (1) IE911707A1 (de)
IL (3) IL98175A (de)
TW (1) TW216771B (de)
ZA (1) ZA913865B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
KR100472793B1 (ko) * 1995-10-26 2005-06-16 사노피-신델라보 근위축성측삭경화증치료용약제를제조하기위한1-(2-나프트-2-일에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피리딘의용도
ATE346303T1 (de) * 1996-03-29 2006-12-15 Univ Boston Mit alzheimer krankheit verknüpften verfahren zur diagnose, zur herstellung von medikamenten und zum screenen von substanzen sowie aus beta- amyloid abgeleiteten peptiden
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
JP2001511141A (ja) * 1997-02-03 2001-08-07 サノフィ−サンテラボ １−［４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリド−１−イル］−２−（６，７−ジメトキシナフト−２−イル）エタンの、脳障害および神経障害を治療する目的の薬剤を調製するための使用
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
IE911707A1 (en) 1991-12-04
KR0181330B1 (ko) 1999-03-20
IL112167A (en) 1996-01-31
JPH04226917A (ja) 1992-08-17
EP0458696A2 (de) 1991-11-27
CA2365832C (en) 2007-08-07
IL98175A (en) 1996-01-19
DK0655247T3 (da) 2002-02-18
AU636488B2 (en) 1993-04-29
DE69132797T2 (de) 2002-05-29
CA2365832A1 (en) 1991-11-23
ATE207747T1 (de) 2001-11-15
HK1001471A1 (en) 1998-06-19
JP2954029B2 (ja) 1999-09-27
US5270320A (en) 1993-12-14
CA2042974C (en) 2002-09-17
US5229389A (en) 1993-07-20
JPH09132535A (ja) 1997-05-20
FR2662355A1 (fr) 1991-11-29
DE69132797D1 (de) 2001-12-06
EP0458696B1 (de) 1996-01-03
KR910019617A (ko) 1991-12-19
HU911729D0 (en) 1991-12-30
DK0458696T3 (da) 1996-05-20
IE20011078A1 (en) 2002-03-20
TW216771B (de) 1993-12-01
FR2662355B1 (fr) 1994-11-10
DE69115989T2 (de) 1996-08-22
CY2283B1 (en) 2003-07-04
BR9105015A (pt) 1993-05-25
JP2618115B2 (ja) 1997-06-11
ZA913865B (en) 1992-02-26
EP0458696A3 (en) 1992-03-18
AU7713391A (en) 1991-11-28
IL98175A0 (en) 1992-06-21
EP0655247B1 (de) 2001-10-31
CA2042974A1 (en) 1991-11-22
ATE132369T1 (de) 1996-01-15
HUT59824A (en) 1992-07-28
HU208922B (en) 1994-02-28
EP0655247A1 (de) 1995-05-31
IL112167A0 (en) 1995-03-15
US5468753A (en) 1995-11-21

Similar Documents

Publication Publication Date Title
DE69115989D1 (de) Verwendung von 1-(2-Naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur Herstellung eines Medikaments zur Behandlung von zerebralen und neuronalen Krankheiten
DE69435246D1 (de) Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung der senilen Demenz und Alzheimer-Erkrankung
DE69524679D1 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
DE68908971T2 (de) Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen.
DE69534002D1 (de) Verwendung von Phosphatidylserinen zur Herstellung eines Arzneimittels zur Verbesserung der Gehirntätigkeit
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
ATE75942T1 (de) Verwendung von 2-amino-4-morpholino-6-propyl1,3,5-triazin zur herstellung eines medikaments zur behandlung kognitiver und mentaler erkrankungen.
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
NO901303D0 (no) Nye benzotiopyranylaminer.
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
DE69300037T2 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
EP0230863A3 (de) Oxadiazinone
DE59701514D1 (de) Verfahren zur bestimmung der phototoxizität und/oder photosensibilität von stoffen oder stoffgemischen sowie dessen verwendung
Gilden Dual action effects of morphine on the electrical activity of the dorsal tegmentum
DE59913720D1 (de) Verfahren zur Herstellung eines Extraktes aus Copalchirinde und Verwendung der Neoflavonoide zur Behandlung von Diabetes
DE68907178T2 (de) Verfahren zur behandlung von quaternaeren oniumsalzen und dessen verwendung bei der herstellung von hexafluorpropylenoxid.
DE69228235D1 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
PT66533A (de) 2-(dimethylcarbamoylimino)-1,3,4-thiadiazolin-3-carbons#ure-ester,verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-SYNTHELABO, PARIS, FR

8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR